SynthesisBMC anesthesiology2025
Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy: a systematic review of the past decade (2014-2023).
Synthesis in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExtracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) are often used together to treat critically ill patients. This systematic review aims to assess mortality and renal recovery with this combination as reported by studies published over the past decade.
methodsWe searched PubMed, Web of Science, ProQuest Health & Medical Complete, Embase, and Ovid SP. Two reviewers independently screened studies and extracted data. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) for non-randomized controlled trials. We performed statistical analyses with RevMan 5.4.
resultsNineteen studies with 1,786 patients met the inclusion criteria. Of these, 1,021 patients were in the ECMO-alone group (495 deaths, 48.5, %) and 765 were in the ECMO with CRRT group (395 deaths, 51.6%). The pooled effect showed no statistically significant difference in mortality between groups (OR 1.2, 95% CI 0.99-1.46, p = 0.07), though heterogeneity was high (I
conclusionIn conclusion, in contrast to older data, our pooled analysis of recent studies revealed no significant increase in mortality risk associated with CRRT use in patient treated with ECMO. However, after accounting for heterogeneity, mortality remained higher in patients treated with ECMO and CRRT group than in the ECMO-alone group. Additional prospective data are essential to clarify the impact of CRRT on outcomes in patients treated with ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.